Develops and manufactures specialty performance ingredients. Offers solutions for human nutrition and health. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
The market pays 34.6× for every dollar this company earns in a year — a price that already assumes things go well.
Against companies in its own sector, it looks cheaper than 32% of them.
Analysts' average target sits 29% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly below the class average.
This grade is a blend: the profit side is strong, the sales tempo slow.
The price is looking for direction — no strong breakout, no collapse.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
The stock trades below its recent peak — about 9% off the top. A pullback, not a collapse.
Over the last 12 months, company executives reported 37 buys and 34 sells. Management buying with its own money is usually read as a good sign.
It pays out $0.96 per share each year — regular cash for whoever holds the stock.
The company’s market value is 35 times its annual profit. Even a small disappointment could hit the price hard.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 32/100.
The price action doesn’t yet back an upward turn.
On our five-subject report card, BCPC sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: BCPC is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (32/100) says the stock isn’t cheap.